SPEX: Read their history of stock offering here
Read the following, and do your DD:
Jan 11, 2012:
SPEX today reported the successful completion of its 28-day rat toxicology study of its drug candidate, SPX-106.
Feb. 2, 2012:
Spherix Announces Registered Direct Offering of $1.15 Million
===================================================== ========
10/24/11:
Spherix today announced that SPX-106T (the combination of D-tagatose and SPX-106) reduced dyslipidemia in new studies of apolipoprotein E-deficient mice and Syrian Golden hamsters.
10/26/11:
SPHERIX TO RAISE $1.25 MILLION IN PRIVATE PLACEMENT
===================================================== =====
Morning of Oct. 7, 2010:
Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
Afternoon of Oct. 7, 2010:
Spherix Announces Institutional Investors Purchase $5.25 Million of Convertible Preferred Stock and Warrants
================================================
Morning of 11/16/09 - Spherix Announces Positive Interim Results In Phase 3 Trial of Novel, Oral Compound for Type 2 Diabetes
Afternoon of 11/16/09 - Spherix Incorporated to Raise $6.3 Million in Registered Direct Offering